Phaseline

Targets › CALCB

CALCB (Calcitonin gene-related peptide 2): drug programs, companies and trials

2 programs from 2 companies in 6 trials: 6 Phase 3; Neurology; next expected readout Nov 2026.

CALCB/CGRP2 is a peptide hormone that induces vasodilation mediated by the CALCRL-RAMP1 receptor complex. Dilates a variety of vessels including the coronary, cerebral and systemic vasculature. (UniProt, P10092)

Open in Phaseline: the race on CALCB, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Eli LillyGalcanezumab (LY2951742)
Calcitonin gene-related peptide inhibitor
CALCA, CALCBPhase 3Episodic Migraine; Chronic MigraineNov 2026
H. LundbeckEptinezumab
Calcitonin gene-related peptide inhibitor
CALCA, CALCBPhase 3Chronic Migraine in Children; Episodic Migraine; Migraine; Post Traumatic HeadacheMar 2027

Conditions

Episodic Migraine (2) Chronic Migraine in Children (1) Migraine (1) Post Traumatic Headache (1) Chronic Migraine (1)

Modalities

antibody (2)

Companies

H. Lundbeck (1) Eli Lilly (1)

Related targets

CALCA (2)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.